Evidence map›Paper›PMID 38387989›Full record

Trial reportBMJ open2024

Randomised, blinded, cross-over evaluation of the palatability of and preference for different potassium binders in participants with chronic hyperkalaemia in the USA, Canada and Europe: the APPETIZE study.

David C Wheeler, Henning Søndergaard, Cathy Gwynn, Katarina Hedman, Jonatan Hedberg, Alaster Allum, Hui-Lan Chung, Mats Någård, Gunilla Stjernlöf, Eric Wittbrodt and 2 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IVRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04566653 (Non-Interventional, Exploratory, Phase IV, Single-Blind, Cross-Sectional, Randomised, Cross-over Study Evaluating Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease & Hyperkalaemia), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04566653 completednot on this map

Non-Interventional, Exploratory, Phase IV, Single-Blind, Cross-Sectional, Randomised, Cross-over Study Evaluating Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease & Hyperkalaemia (APPETIZE).

TypeobservationalSponsorAstraZenecaRan2020 to 2022Enrolled147ConditionsChronic Kidney Disease + Hyperkalaemia +/- Heart FailureArmsCalcium Polystyrene Sulphonate 15g/60 mL water, Lokelma® 5 g/45mL water, Lokelma® 10 g/45 mL water, Veltassa® 8,4 g/80mL water, Sodium Polystyrene Sulphonate 15g/60 mL water
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 6 countries.

David C WheelerDepartment of Renal Medicine, Centre for Nephrology, University College London, London, UK d.wheeler@ucl.ac.uk.ORCID 0000-0003-0745-3478
Henning SøndergaardDanish Kidney Association, Taastrup, Denmark.
Cathy GwynnAdSAM, Gainesville, Florida, USA.
Katarina HedmanBioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Jonatan HedbergBioPharmaceuticals Medical Evidence and Observational Research, AstraZeneca, Gothenburg, Sweden.
Alaster AllumUK Global Medical Affairs, AstraZeneca, Cambridge, UK.
Hui-Lan ChungBioPharmaceuticals Medical Evidence, AstraZeneca, Taipei, Taiwan.
Mats NågårdClinical Pharmacology and Safety Sciences, AstraZeneca, Gaithersburg, Maryland, USA.
Gunilla StjernlöfGlobal Patient Safety, AstraZeneca, Gothenburg, Sweden.
Eric WittbrodtGlobal Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.
Jennifer KimGlobal Pricing and Market Access, AstraZeneca, Gaithersburg, Maryland, USA.
Jon MorrisAdSAM, Gainesville, Florida, USA.
AstraZeneca (Brazil) · BRAfrican University College of Communications · GHAstraZeneca (United Kingdom) · GBDanish Diabetes Association · DKUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTraditional potassium (K

designPhase 4, randomised, participant-blinded, cross-over study. Participants were randomised to one of six taste sequences and, using a 'sip and spit' approach, tasted each K

setting17 centres across the USA, Canada and European Union.

participants144 participants with chronic kidney disease, hyperkalaemia and no recent use of K

main outcome measuresFor the primary (USA) and key secondary (Canada and European Union) endpoints, participants rated palatability attributes (taste, texture, smell and mouthfeel) and willingness to take each K

resultsIn each region, SZC and patiromer outperformed S/CPS on overall palatability (a composite of taste, texture, smell and mouthfeel), based on rational evaluation and emotional response. Taking the product once daily was more appealing for SZC and patiromer, creating greater receptivity than the idea of taking S/CPS. The emotional response to mouthfeel had the strongest influence on feelings about taking each product. In each region, a numerically greater proportion of participants ranked SZC as the most preferred K

conclusionsPreference for more palatable K TRIAL REGISTRATION NUMBER: NCT04566653.

Indexed as

HyperkalemiaRenal Insufficiency, ChronicSilicatesCanadaCross-Over StudiesHumansPotassiumSingle-Blind MethodPotassiumSilicatessodium zirconium cyclosilicateChronic renal failureClinical TrialNephrologyPatient-Reported Outcome Measures

Identifiers

PMID38387989
PMCPMC10882352
OpenAlexW4392059441

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.